title: Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
abstract: OBJECTIVE
  To compare the cost-effectiveness between actinomycin D (Act-D) and methotrexate-folinic acid (MTX-FA) in the treatment of low-risk gestational trophoblastic neoplasia (GTN) in the Thai population.
  
  
  METHODS
  A comparative cost-effectiveness analysis was performed from a societal perspective. A decision tree model was developed comparing 2 alternative treatment options: initial 5-day Act-D and 8-day MTX-FA. Treatment would be switched to another regimen in case of resistance. The outcome of interest is number of days to remission. Clinical data was obtained from our previous study in which Act-D demonstrated 100% remission rates as compared to 73.6% for MTX-FA. Cost of treatment data, which includes chemotherapeutics, accessory medications, laboratory tests, and hospital fees, was obtained from a university hospital. Patient-related travel cost and opportunity cost due to absence from work were also included. All costs were calculated to 2015 base year.
  
  
  RESULTS
  Costs per treatment cycle were $308.01 and $227.20 US dollars (USD) for 5-day Act-D and 8-day MTX-FA, respectively. Expected time toward treatment completion for Act-D was 12.6 days shorter than for MTX-FA. Expected costs toward remission for initial treatment with Act-D and MTX-FA were $1,078.04 and $1,064.56 USD, respectively, i.e., an incremental cost effectiveness ratio (ICER) of $1.07 USD/day of earlier treatment completion. After sensitivity analysis, remission rate of lower than 72% would make initial treatment with MTX-FA more expensive than with Act-D.
  
  
  CONCLUSIONS
  Treatment costs of low-risk GTN are almost equal between the 2 treatment options with different time to remission. Initial treatment with MTX-FA is slightly less expensive, but there is longer time to remission. The ICER of initial treatment with Act-D over MTX-FA is $1.07 USD/day of earlier treatment completion.
authors.forename: Arb-Aroon
authors.initials: AA
authors.lastname: Lertkhachonsuk
authors.forename: Piya
authors.initials: P
authors.lastname: Hanvoravongchai
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000191:economics / Q000627:therapeutic use*; D000932:Antiemetics / Q000191:economics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D019411:Clinical Laboratory Techniques / Q000191:economics; D003362:Cost-Benefit Analysis; D003609:Dactinomycin / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy*; D017048:Health Care Costs; D005102:Health Expenditures; D006397:Hematinics / Q000191:economics / Q000627:therapeutic use; D006785:Hospitals, University; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000191:economics; D008727:Methotrexate / Q000008:administration & dosage / Q000191:economics; D011247:Pregnancy; D012074:Remission Induction; D013785:Thailand; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000932:Antiemetics; D006397:Hematinics; D003609:Dactinomycin; D002955:Leucovorin; D008727:Methotrexate